Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients.

Biomed Res Int · 2014 · PMC4086227 · PMID 25032217

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

not significantly significantno p-value reported

showed lower PFS and OS in BRAF V600E mutated patients compared with wild-type (4.2 versus 11.1 months and 14.3 versus 35.0 months, resp.), although differences were not significantly significant [ 31 ].

also in 164 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.